JP7396991B2 - 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物 - Google Patents

癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物 Download PDF

Info

Publication number
JP7396991B2
JP7396991B2 JP2020547036A JP2020547036A JP7396991B2 JP 7396991 B2 JP7396991 B2 JP 7396991B2 JP 2020547036 A JP2020547036 A JP 2020547036A JP 2020547036 A JP2020547036 A JP 2020547036A JP 7396991 B2 JP7396991 B2 JP 7396991B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
group
administering
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020547036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517134A5 (https=
JP2021517134A (ja
JPWO2019170750A5 (https=
Inventor
ベイカー，ウィリアム・アール
Original Assignee
アムジェン（ユーロップ）ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジェン（ユーロップ）ゲーエムベーハー filed Critical アムジェン（ユーロップ）ゲーエムベーハー
Publication of JP2021517134A publication Critical patent/JP2021517134A/ja
Publication of JP2021517134A5 publication Critical patent/JP2021517134A5/ja
Publication of JPWO2019170750A5 publication Critical patent/JPWO2019170750A5/ja
Application granted granted Critical
Publication of JP7396991B2 publication Critical patent/JP7396991B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2020547036A 2018-03-07 2019-03-06 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物 Active JP7396991B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07
US62/639,650 2018-03-07
PCT/EP2019/055576 WO2019170750A1 (en) 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases

Publications (4)

Publication Number Publication Date
JP2021517134A JP2021517134A (ja) 2021-07-15
JP2021517134A5 JP2021517134A5 (https=) 2022-03-15
JPWO2019170750A5 JPWO2019170750A5 (https=) 2022-03-15
JP7396991B2 true JP7396991B2 (ja) 2023-12-12

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020547036A Active JP7396991B2 (ja) 2018-03-07 2019-03-06 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物

Country Status (11)

Country Link
US (1) US11639332B2 (https=)
EP (1) EP3762365B1 (https=)
JP (1) JP7396991B2 (https=)
AR (1) AR114666A1 (https=)
AU (1) AU2019229583B2 (https=)
CA (1) CA3093196A1 (https=)
ES (1) ES2987705T3 (https=)
MA (1) MA52266A (https=)
MX (1) MX2020009288A (https=)
TW (1) TW202000646A (https=)
WO (1) WO2019170750A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531845A (ja) 2007-06-29 2010-09-30 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 胃腸疾患の治療のための標的指向化ジアゾプロドラッグ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JPWO2002001667A1 (ja) * 2000-06-29 2004-01-08 日本化薬株式会社 色素増感光電変換素子
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
CA2718601A1 (en) 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
MX347928B (es) 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531845A (ja) 2007-06-29 2010-09-30 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 胃腸疾患の治療のための標的指向化ジアゾプロドラッグ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，1999年，Vol.9，pp.1625-1630

Also Published As

Publication number Publication date
AR114666A1 (es) 2020-09-30
AU2019229583A1 (en) 2020-09-10
MA52266A (fr) 2021-01-13
CA3093196A1 (en) 2019-09-12
EP3762365A1 (en) 2021-01-13
TW202000646A (zh) 2020-01-01
ES2987705T3 (es) 2024-11-15
AU2019229583B2 (en) 2024-06-13
JP2021517134A (ja) 2021-07-15
US20200392082A1 (en) 2020-12-17
US11639332B2 (en) 2023-05-02
WO2019170750A1 (en) 2019-09-12
MX2020009288A (es) 2020-09-28
EP3762365B1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
EP2046727B1 (en) Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate
WO2008093173A1 (en) Positively charged water-soluble prodrugs of 1h-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
EP2623495B1 (en) Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
BR112019020691A2 (pt) Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
JP2010502583A (ja) 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
BR112020010429A2 (pt) uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
JP5378221B2 (ja) 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ
WO2008012603A1 (en) Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
RS65256B1 (sr) Upotreba nmn za prevenciju i/ili lečenje bola i odgovarajuće kompozicije
BR112020014584A2 (pt) inibição do canal iônico do receptor de potencial transitório a1
JP7396991B2 (ja) 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物
WO2023142729A1 (zh) 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途
ES2363056T3 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-óxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la médula espinal.
US20120202860A2 (en) Analgesic Compounds, Compositions and Uses Thereof
CN111320635B (zh) 用于治疗骨关节炎的化合物
CN118496144A (zh) 蟾蜍色胺衍生物及其在镇痛、抗抑郁药物中的应用
JPH0755906B2 (ja) ジサツカライド誘導体含有鎮痛剤
US20070004777A1 (en) Methods for treating or preventing acute myelogenous leukemia
AU2008257319B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
CN119925347B (zh) 化合物Pladienolide B作为抗蓖麻毒素保护剂的医药用途
WO2024002112A1 (zh) 一种治疗猫冠状或杯状病毒感染的方法
CN104706630B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药
CN103980228B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
CN121226330A (zh) 取代的哌啶类化合物及其药物组合物、制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231130

R150 Certificate of patent or registration of utility model

Ref document number: 7396991

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150